Shots:

• Boston Scientific signs an agreement with Stark International and SERB SAS to sell its BTG specialty pharma business for $800M in cash. The transaction is expected to close in H1’21
• The agreement includes the transfer of 5 facilities & ~280 employees globally. This transaction will help the BTG specialty pharma business enhance its potential as a fully integrated specialty pharmaceuticals platform
• Boston Scientific acquired BTG for ~$3.7B in 2019. The divested products include life-saving antidotes used in hospitals & emergency care settings- including CroFab- DigiFab & Voraxaze

 ­ Ref: PRNewswire | Image: Barron's